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Abstract
Background: Medicinal plants represent alternative means for the treatment of several chronic
diseases, including inflammation. The genus Ranunculus, a representative of the Ranunculaceae
family, has been reported to possess anti-inflammatory, analgesic, antiviral, antibacterial,
antiparasitic and antifungal activities, possibly due to the presence of anemonin and other. Different
studies have shown the occurrence of unusual fatty acids (FAs) in Ranunculaceae; however, their
therapeutic role has not been investigated. The purpose of this study is to characterize potential
anti-inflammatory  bioactivities in Ranunculus constantinopolitanus  D'Urv., traditionally used in
Eastern Mediterranean folk medicine.
Methods: The aerial part of R. constantinopolitanus was subjected to methanol (MeOH) extraction
and solvent fractionation. The bioactive fraction (I.2) was further fractionated using column
chromatography, and the biologically active subfraction (Y2+3) was identified using infrared (IR)
spectroscopy, nuclear magnetic resonance (NMR) and gas chromatography-mass spectrometry
(GC-MS). The effects of I.2 and Y2+3 on cell viability were studied in mouse mammary epithelial
SCp2 cells using trypan blue exclusion method. To study the anti-inflammatory activities of I.2 and
Y2+3, their ability to reduce interleukin (IL)-6 levels was assessed in endotoxin (ET)-stimulated
SCp2 cells using enzyme-linked immunosorbent assay (ELISA). In addition, the ability of Y2+3 to
reduce cyclooxygenase (COX)-2 expression was studied in IL-1-treated mouse intestinal epithelial
Mode-K cells via western blotting. Data were analyzed by one-way analysis of variance (ANOVA),
Student-Newman-Keuls (SNK), Tukey HSD, two-sample t-test and Dunnett t-tests for multiple
comparisons.
Results: The chloroform fraction (I.2) derived from crude MeOH extract of the plant, in addition
to Y2+3, a FA mix isolated from this fraction and containing palmitic acid, C18:2 and C18:1 isomers
and stearic acid (1:5:8:1 ratio), reduced ET-induced IL-6 levels in SCp2 cells without affecting cell
viability or morphology. When compared to fish oil, conjugated linoleic acid (CLA) and to individual
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FAs as palmitic, linoleic, oleic and stearic acid or to a mix of these FAs (1:5:8:1 ratio), Y2+3 exhibited
higher potency in reducing ET-induced IL-6 levels within a shorter period of time. Y2+3 also reduced
COX-2 expression in IL-1-treated Mode-K cells.
Conclusion: Our studies demonstrate the existence of potential anti-inflammatory bioactivities in
R. constantinopolitanus and attribute them to a FA mix in this plant.
Background
Dietary supplements are used as preventive means to
maintain a healthy state. Among them, polyunsaturated
fatty acids (PUFAs), specifically members of the omega
(n)-3 series and conjugated linoleic acid (CLA), have
become the focus of extensive nutritional research in the
last decade [1-6] due to their reported anti-inflammatory
properties. Indeed, CLA and the n-3 eicosapentaenoic acid
(EPA) and docosahexaenoic acid (DHA) were found to
reduce the levels of many inflammatory mediators,
including cytokines: interleukin (IL)-1, IL-6 and tumor
necrosis factor (TNF)-α, eicosanoids: prostaglandins
(PGs), thromboxanes (TXs) and leukotrienes (LTs),
enzymes: cyclooxygenase (COX)-2 and 5-lipoxygenase
(LOX), adhesion molecules: E-selectin, intercellular adhe-
sion molecule (ICAM)-1 and vascular cell adhesion mole-
cule (VCAM)-1 and matrix metalloproteinases (MMPs)
[7-10]. Clinically, reports have suggested that supplemen-
tation with n-3 fatty acids (FAs) has beneficial effects in
chronic inflammatory diseases such as inflammatory
bowel disease (IBD), rheumatoid arthritis (RA) and pso-
riasis [11]. Moreover, adding n-3 FAs to the diet of
patients with hypertriglyceridemia is now recognized as
an efficient triglyceride-lowering therapeutic measure
[12]. CLA has been shown to possess similar effects,
though the safety and efficacy of CLA dietary supplements
is still under investigation [9,13,14].
In contrast to the numerous reports investigating the pro-
tective effects of animal-derived PUFAs in inflammation,
the literature describing anti-inflammatory bioactivities in
plant-derived FAs, and particularly those existing in the
Ranunculaceae family, used as a medicinal herb, is poor.
This family, comprising around 2500 species distributed
all over the world, is especially widespread in slow
streams, ditches and shallow ponds of muddy mineral-
rich water. Ranunculus, a representative genus of the
Ranunculaceae family, has been established as an anti-
inflammatory, analgesic, antiviral, antibacterial, antipara-
sitic and antifungal agent [15-20]. Such properties of this
genus could be due to the presence of anemonin, a dimer-
ization product of the γ-lactone protoanemonin, both of
which have been shown to possess several pharmacologi-
cal effects [18,21-23]. In this paper, the effect of a FA mix
extracted from Ranunculus constantinopolitanus D'Urv., an
Eastern Mediterranean plant that extends as far as Arme-
nia, on endotoxin (ET)-induced IL-6 and IL-1-induced
COX-2 in SCp2 and Mode-K cells, respectively, is investi-
gated. This effect is subsequently compared to the activi-
ties of over-the-counter products reported to modulate
inflammation, including fish oil and CLA.
Methods
Cell culture
Mouse mammary epithelial cell strain, SCp2 cells (kindly
provided as a gift by P.Y. Desprez, Geraldine Brush Cancer
Research Institute, California Pacific Medical Center, San
Francisco, CA, USA) were cultured as previously described
by Saliba et al. (2009) [24]. Briefly, cells were grown on
100-mm tissue culture plates (BD Falcon, Franklin Lakes,
NJ, USA) in growth medium (GM) consisting of Dul-
becco's Modified Eagle's Medium Nutrient Mixture/F12
Ham (DMEM/F12; Gibco, Paisley, Scotland) supple-
mented with 5% heat-inactivated fetal bovine serum (FBS;
Gibco), insulin (5 μg/ml; Sigma, St. Louis, MO, USA) and
1% penicillin/streptomycin mixture (Gibco) in a humidi-
fied incubator (95% air 5% CO2; VWR Scientific, West
Chester, PA, USA) at 37°C. Upon confluency, cells were
detached by trypsinization and replated in GM either on
100-mm tissue culture plates for maintenance or on 6-
well plates (BD Falcon) at 1 × 106 cells/well to be used in
different experiments. On the second day after plating,
cells were shifted to differentiation medium (DM) con-
sisting of DMEM/F12 supplemented with insulin (5 μg/
ml), hydrocortisone (1 μg/ml; Sigma), ovine prolactin (3
μg/ml; Sigma) and 1% penicillin/streptomycin. On the
third day, unless otherwise indicated, plant and ET treat-
ments were performed in triplicates.
Murine intestinal epithelial cell type Mode-K cells were
cultured as previously described by Homaidan et al.
(2003) [25]. Briefly, cells were maintained in DMEM con-
taining 1 g/L glucose and 10 mM sodium pyruvate (Invit-
rogen, Carlsbad, CA, USA) and supplemented with 10%
FBS (Invitrogen), 1% non-essential amino acids (Invitro-
gen) and 0.5% penicillin/streptomycin (Invitrogen). At
70-80% confluency, cells were detached by trypsinization
and replated on tissue culture flasks (BD Falcon) for
maintenance or on 6-well plates at 2 × 105 cells/well to be
used in different experiments. On the second day after
plating, cells were starved. Plant and IL-1 treatments were
performed on the second and third days.BMC Complementary and Alternative Medicine 2009, 9:44 http://www.biomedcentral.com/1472-6882/9/44
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Extraction of plant material
Collection and drying
Ranunculus constantinopolitanus was collected from Yanta,
Lebanon, located at an altitude of 1395 m. A voucher
specimen of the plant (voucher number: 72) was depos-
ited at the Post Herbarium of the American University of
Beirut, Beirut, Lebanon. Following collection, the aerial
part (stems, leaves and flowers) of R. constantinopolitanus
was dried by leaving the plant sample in the shade for two
weeks before grinding it into approximately 10-mm
pieces using a blender. Ground samples were subjected to
solvent extraction using methanol (MeOH) or else they
were stored at -20°C for later use.
Methanol extraction and fractionation
The crude MeOH extract was subjected to further solvent
fractionation as previously described by Saliba et al.
(2009) [24]. In brief, the dried plant material was sub-
jected to extraction through soaking in MeOH (1:10 w/v)
for 16 hr. Incubation on a shaker at 20°C occurred in the
first 2 hr, and then the plant sample was left in MeOH for
the remaining time. The MeOH extract was filtered using
a cheese cloth (sterile gauze sponges 30 × 30 cm) to give a
solid phase (R-I) and a filtrate numbered "I" and referred
to as "crude MeOH extract". R-I was soaked in ethyl ace-
tate (EtOAc) at a ratio of 10:1 (w/v). It was then separated
by filtration into a solid phase and a filtrate numbered
"I.1". The crude MeOH extract (I) was evaporated to 1/10
of its volume at less than 40°C, acidified to pH 2 by con-
centrated H2SO4 and then separated into an aqueous and
an organic layer using a mixture of CHCl3 and H2O (2:1
v/v). The organic layer was collected and labelled as "I.2".
The aqueous layer was basified to pH 10 by the addition
of concentrated NH4OH and was then resuspended in a
mixture of CHCl3 and MeOH (3:1 v/v) (the total volume
of CHCl3:MeOH is equal to four times the volume of the
aqueous layer) to be later separated into an organic layer
and an aqueous layer labelled as "I.3" and "I.4", respec-
tively. I.1, I.2, I.3 and I.4 were evaporated to dryness
under vacuum, weighed, dissolved in 100% ethanol
(EtOH) and stored in dark bottles at -20°C. The fractions
were subsequently screened for potential biological activ-
ities, and the active ones were selected for further purifica-
tion.
Separation and identification of subfraction Y2+3
Biologically active fraction I.2 (6 g) was re-dissolved in a
minimum volume of petroleum ether (P.ether):
CHCl3:EtOAc mixture (2:2:1) and was applied to a col-
umn chromatography consisting of 800 g of silica gel. A
gradient elution was performed using P.ether:
CHCl3:EtOAc (2:2:1) (6500 ml), followed by P.ether:
CHCl3:EtOAc (1:3:1) (4000 ml), CHCl3: EtOAc:MeOH
(3:3:1) (4200 ml) and MeOH, successively. Subfraction
Y2+3 was collected using P.ether:CHCl3:EtOAc (2:2:1) as a
mobile phase.
Y2+3, which had the highest biological activity, was puri-
fied via solid phase extraction (SPE). Spectroscopic data
using infrared (IR) spectroscopy and nuclear magnetic res-
onance (NMR) showed that Y2+3 was a mixture of FAs. The
mixture was consequently converted to FA methyl esters
(FAMEs) and resolved into individual components using
gas chromatography-mass spectrometry (GC-MS). GC
analysis was performed using a Trace™ gas chromatograph
equipped with HP-5 capillary column (30 m long, 250
μm i.d and 0.25 μm film thickness), Helium as a carrier at
a flow rate of 1 ml/min. The maximum temperature was
350°C. The column was heated from 35°C to 290°C. The
injector temperature was set at 300°C in a splitless mode.
Results were recorded as percent of total peak areas. The
mass spectrometer employed in the GC-MS analysis was a
Polarization Q series mass selective detector in the elec-
tron impact (EI) ionization mode (70 eV). Using appro-
priate reference standards of FAMEs, Y2+3 was identified as
a mixture of four FAs: palmitic acid (C16:0), isomers of
C18:2 and C18:1 and stearic acid (C18:0) in the corre-
sponding proportion 1:5:8:1.
Treatment of cells with plant extracts and fatty acids
Plant extracts, fish oil, CLA, the FAs: palmitic, linoleic (cis-
9, cis-12-octadecadienoic acid), oleic (cis-9-octadecenoic
acid) and stearic acid and a mix of the four FAs (1:5:8:1
ratio) were all diluted in 100% EtOH and stored at -20°C.
On day 3 after plating, SCp2 cells were treated with plant
extracts or other FA compounds at different concentra-
tions in DM supplemented with 1% FBS up to a final vol-
ume of 1 ml/well. Following treatment, cells were
incubated at 37°C for different time points (24 or 48 hr)
to assess cytotoxicity or for 30 min (short-term treatment)
before ET treatment. For other experiments, media were
supplemented with plant extracts or other FA compounds
at different concentrations for 3 days as of the plating day
(long-term treatment), and cells were treated with ET on
day 3.
For Mode-K cells, on day 2 after plating, cultures were pre-
treated with Y2+3 or a synthetic FA mix at different concen-
trations in the absence of FBS up to a final volume of 1 ml/
well. Following treatment, cells were incubated at 37°C
for 8 or 12 hr before IL-1 treatment on day 3. Another
method involved the cotreatment of Mode-K cells with
Y2+3 or a synthetic FA mix and IL-1 on day 3 for 8 hr under
similar conditions.
Induction of inflammation
Endotoxin treatment of SCp2 cells
ET treatment was performed as previously described by
Saliba et al. (2009) [24]. Salmonella typhosa ET (Sigma)
was dissolved in DM, filter-sterilized using 0.2 μm non-
pyrogenic sterile-R filter and stored at -20°C. On day 3
after plating, cells were treated with ET at 10 μg/ml and
then incubated at 37°C for 9 hr.BMC Complementary and Alternative Medicine 2009, 9:44 http://www.biomedcentral.com/1472-6882/9/44
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Interleukin-1 treatment of Mode-K cells
IL-1 treatment was performed as previously described by
Homaidan  et al. (2003) [25]. IL-1α (US Biological,
Swampscott, MA, USA) was dissolved in 1% bovine serum
albumin (BSA; Invitrogen) and stored at -20°C. On day 3
after plating, cells were treated with IL-1 at 10 ng/ml and
then incubated at 37°C for 6 or 8 hr.
Trypan blue exclusion method
Twenty-four or 48 hr post plant treatment, viable and
dead SCp2 cells were counted using the trypan blue exclu-
sion method. It involves the trypsinization of the attached
cells and washing them using the same treatment
medium, which contains dead cells, to form a suspension
of the total treated cells. An aliquot of 50 μl is taken from
this suspension and mixed with an equal volume of
trypan blue (Gibco). Dead cells stain blue, while viable
cells appear bright. The percentage of viability is calcu-
lated relative to the control.
Enzyme-linked immunosorbent assay (ELISA)
Sample collection
Media of SCp2 cells were sampled from triplicate wells 9
hr post ET treatment. Forty μl of complete protease inhib-
itors [one tablet dissolved in 2 ml of double distilled
water (DDW); Roche Diagnostics GmbH, Mannheim,
Germany] was added to each 1 ml of sample. Samples
were stored at -80°C until the day of the assay.
Interleukin-6 assay
A two-site (sandwich) ELISA was performed for the quan-
titative determination of mouse IL-6 (mIL-6) present in
SCp2 cell culture media, using mIL-6 ELISA immunoassay
kit (BioSource International, Inc., Camarillo, CA, USA).
The IL-6 assay was performed according to manufacturers'
instructions. All standards and samples were run in dupli-
cates on high-binding 96-well microtiter plates (Thermo
Labsystems, Philadelphia, PA, USA). The optical density
was measured at a wavelength of 450 nm by an ELISA
microplate reader (Multiskan Ascent, Thermo Labsys-
tems). Concentrations were calculated using the Ascent
software and were expressed in pg/ml.
Western blotting
Mode-K cells were washed twice with phosphate-buffered
saline (PBS) and scraped in 2× electrophoresis sample
buffer (SB) containing 0.25 M Tris-HCl (pH 6.8; Amer-
sham Biosciences, San Diego, CA, USA), 4% w/v sodium
dodecyl sulfate (SDS; Amersham Biosciences), 20% w/w
glycerol (Amersham Biosciences), 0.1% bromophenol
blue and 40 μl/ml protease inhibitor cocktail (Biomol,
Plymouth Meeting, PA, USA). Samples were then col-
lected in microfuge tubes, boiled for 5 min, centrifuged
and the supernatant representing total soluble protein
extract was collected and stored at -80°C.
Total protein extracts were run on a 12% SDS-polyacryla-
mide gel (BioRad, Hercules, CA, USA), and the gels were
transferred to polyvinylidene difluoride (PVDF) mem-
branes (Amersham Biosciences) overnight at 4°C. Follow-
ing transfer, membranes were washed once with TPBS
wash buffer (PBS containing 0.1% Tween 20) and then
blocked in 5% non-fat dry milk for 2 hr at room tempera-
ture. Rabbit polyclonal COX-2 antibody (Cayman Chem-
ical, Ann Arbor, MI, USA) was then added to the
membranes and incubated for 2 hr at room temperature.
Unbound antibodies were washed three times with TPBS.
Horse-raddish peroxidase (HRP)-conjugated anti-rabbit
IgG (Santa Cruz Biotechnology, Santa Cruz, CA, USA) was
added at 1:5000 dilution for 1 hr at room temperature.
Membranes were washed, incubated with luminol rea-
gents (Santa Cruz Biotechnology) and directly exposed to
autoradiography.
Statistical analysis
Data were expressed as mean ± S.D. The effectiveness of
plant treatments was analyzed by one-way analysis of var-
iance (ANOVA). To check for treatments with similar
effects, Student-Newman-Keuls (SNK) and Tukey HSD
tests were performed. The effect of each treatment, if any,
was then compared to the control using two-sample t-test
or Dunnett t-tests for multiple comparisons. All statistical
analyses were carried out using statistical program for
social sciences (SPSS) 11.5, except for t-test, which was
performed using Excel. Statistical probability of P < 0.05
was considered significant.
Results
Effect of R. constantinopolitanus extracts on endotoxin-
induced interleukin-6 levels in SCp2 cells
Ranunculus constantinopolitanus (Figure 1), known for its
folk medicinal value, was subjected to chemical extraction
and purification. The crude MeOH extract (I) from this
plant was cytotoxic to SCp2 cells. Accordingly, I.2, the
chloroform fraction derived from that extract, was tested
for its biological activity on SCp2 cells. To determine the
maximum concentration of I.2 that can be used without
affecting cell viability or morphology, SCp2 cells were
treated with I.2 at different concentrations (10, 25, 50 or
100 μg/ml) or EtOH, as a vehicle control, and viable cell
counts were determined. None of the tested concentra-
tions affected cell morphology 24 hr post-treatment (Data
not shown), and cell viability for all concentrations did
not vary significantly from the control treatment (Figure
2A). Thus, the ability of I.2 to inhibit ET-induced IL-6 was
studied to evaluate its potential anti-inflammatory activi-
ties. SCp2 cells pretreated with I.2 at the different concen-
trations (10, 25, 50 or 100 μg/ml) showed, in a
concentration-dependent manner, a significant reduction
in IL-6 levels stimulated by ET (Figure 2B). Basal IL-6 lev-
els were noted in cells pretreated with 100 μg/ml.BMC Complementary and Alternative Medicine 2009, 9:44 http://www.biomedcentral.com/1472-6882/9/44
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Treatment of SCp2 cells with Y2+3 at different concentra-
tions (10, 20 or 30 μg/ml) or EtOH, as a vehicle control,
did not alter cell morphology at any of the tested concen-
trations for up to 48 hr post-treatment (Data not shown).
In addition, cell counts performed at the same time point
showed that cell viability for each concentration was sim-
ilar to that of the control treatment (Figure 3A). Conse-
quently, Y2+3 was used at concentrations not exceeding 30
μg/ml in all subsequent experiments.
To check if the anti-inflammatory effect previously
observed with I.2 was due to the Y2+3 subfraction, the abil-
ity of the latter to inhibit ET-induced IL-6 was evaluated.
SCp2 cells were pretreated with different Y2+3 concentra-
tions, not exceeding 30 μg/ml, using two modes of treat-
ment. Short-term treatment at 5, 10, 15 or 20 μg/ml
resulted in a concentration-dependent downregulation of
ET-induced IL-6 levels (Figure 3B). This reduction was sig-
nificant at all the tested concentrations and exceeded 50%
inhibition at the highest Y2+3 concentration (20 μg/ml).
Long-term treatment at 5 μg/ml significantly downregu-
lated ET-induced IL-6 levels by more than 50% (Figure
3C).
Potency of Y2+3 versus its presumed fatty acid components, 
fish oil or conjugated linoleic acid in regulating endotoxin-
induced interleukin-6 levels in SCp2 cells
The effect of Y2+3 in inhibiting ET-induced IL-6 was com-
pared to that of short- or long-term treatment with each of
the individual FA constituents, i.e. palmitic and stearic
acid and the two most common C18:2 and C18:1 iso-
mers: linoleic (cis-9, cis-12-octadecadienoic acid) and
oleic (cis-9-octadecenoic acid) acid, respectively, at con-
centrations similar to those previously used with Y2+3. It
was noted that Y2+3 significantly reduced ET-induced IL-6
levels upon both short- and long-term treatment of SCp2
cells (Figure 4A and 4B). However, none of the individual
FAs could reduce IL-6 levels at concentrations ranging
from 5-20 μg/ml following short-term treatment (Figure
4A) or at a concentration of 5 μg/ml following long-term
treatment (Figure 4B). Furthermore, neither short-term
treatment at 5-20 μg/ml, nor long-term treatment at 5 μg/
ml with a synthetic mix of palmitic, linoleic (cis-9, cis-12-
octadecadienoic acid), oleic (cis-9-octadecenoic acid) and
stearic acid in the same proportion as in Y2+3 could reduce
ET-induced IL-6 levels (Figure 4A and 4B). In fact, in both
modes of treatment the mix induced higher levels of IL-6
than those induced by ET alone, similarly for linoleate in
short-term treatment and stearate and palmitate in long-
term treatment. Noteworthy is that linoleate was cytotoxic
to cells in long-term treatment mode.
n-3 FAs and CLA are notoriously associated with anti-
inflammatory properties and are available in many forms
as over-the-counter supplements. The ability of fish oil,
containing the n-3 FAs EPA and DHA (1:0.76 ratio), to
reduce ET-induced IL-6 levels was compared to that noted
with Y2+3. SCp2 cells were exposed to short- or long-term
treatment with fish oil at concentrations similar to those
used with Y2+3. In contrast to Y2+3, short-term fish oil treat-
ment did not reduce IL-6 levels induced by ET, but rather
enhanced such levels by at least 40% (Figure 5A). How-
ever, long-term treatment significantly reduced IL-6 to
approximately 25% of the control levels (Figure 5B).
Worth mentioning is the fact that fish oil reduced IL-6 lev-
Ranunculus constantinopolitanus Figure 1
Ranunculus constantinopolitanus. Ranunculus constantinop-
olitanus (Arabic name: Hawdhan fa'ri) is an Eastern Mediterra-
nean plant that grows in Aintab and extends from Hasbayya 
to Jazzin. Description: "Villous below, appressed-hairy above. 
Root-fibers descending directly from neck. Root-leaves trian-
gular-ovate, ternate, with obovate, cut, and coarsely toothed 
lobes. Carpels large, ovate, striate, smooth, ending abruptly 
in a very short, hooked beak". Its flowering season falls 
between April and June [41]. The plant has been identified by 
Dr. Nada Sinno-Saoud, and a voucher specimen (voucher 
number: 72) was deposited at the Post Herbarium of the 
American University of Beirut, Beirut, Lebanon. Photos cour-
tesy of Mr. Khaled Sleem (2004), Crop Production and Pro-
tection Department, Faculty of Agricultural and Food 
Sciences, American University of Beirut, Beirut, Lebanon.BMC Complementary and Alternative Medicine 2009, 9:44 http://www.biomedcentral.com/1472-6882/9/44
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Exposure of SCp2 cells to R. constantinopolitanus fraction I.2 at noncytotoxic concentrations reduces, in a concentration- dependent manner, ET-induced IL-6 levels Figure 2
Exposure of SCp2 cells to R. constantinopolitanus fraction I.2 at noncytotoxic concentrations reduces, in a con-
centration-dependent manner, ET-induced IL-6 levels. SCp2 cells were treated on day 3 of culture with EtOH (Ctrl) 
or I.2 at different concentrations in DM supplemented with 1% FBS: (A) Twenty-four hr later, trypan blue assay was per-
formed. (B) Thirty min later, cells were treated with ET at 10 μg/ml and their media collected 9 hr post-ET. The values 
depicted are the means (± S.D.) of a triplicate treatment. Means with the same letter are not significantly different. Statistical 
significance of the difference from Ctrl+ET is with *P < 0.05, **P < 0.01 or ***P < 0.001. (Ctrl, control; ET, endotoxin; IL-6, 
interleukin-6). -ET (white square); +ET (black square).
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els more than Y2+3 at similar concentrations upon long-
term treatment.
The ability of short- or long-term CLA treatment to reduce
ET-induced IL-6 levels in SCp2 cells was also compared to
that of Y2+3. At noncytotoxic concentrations (0.1, 0.5, 1
and 3 μg/ml), short-term CLA treatment did not reduce IL-
6 levels, except for a marginal, but significant, reduction at
3 μg/ml (Figure 5C). This reduction was less than that
observed with Y2+3 at 10 μg/ml. Following long-term treat-
ment, CLA (0.1, 0.5 or 1 μg/ml) significantly reduced IL-6
levels more so than that noted for Y2+3 at the 0.5 and 1 μg/
ml level (Figure 5D). Concentrations of CLA at 3 and 5 μg/
ml were cytotoxic to cells upon long- and short-term treat-
ment, respectively.
Effect of Y2+3 on interleukin-1-induced cyclooxygenase-2 
expression in Mode-K cells
The effect of Y2+3 on COX-2 protein levels in Mode-K cells
was assessed by pretreating the cells with Y2+3 at 10 μg/ml
for 8 or 12 hr prior to 6-hr treatment with 10 ng/ml of IL-
1 or cotreating cells with Y2+3 and IL-1 for 8 hr. Y2+3 caused
a significant decrease in IL-1-induced COX-2 levels at 12-
hr pretreatment as well as 8-hr cotreatment with IL-1 (Fig-
ure 6A). As with SCp2 cells, the effect of the synthetic mix-
ture of FA components of Y2+3 on COX-2 protein levels in
IL-1-treated Mode-K cells was tested. At 10 μg/ml, a simi-
lar concentration to Y2+3, the synthetic mix did not reverse
the IL-1-induced COX-2 levels in Mode-K cells (Figure 6B,
left panel). The synthetic mix failed to reverse these levels
even at a higher concentration of 60 μg/ml (Figure 6B,
right panel).
Discussion
In this study, we report the existence of anti-inflammatory
activities in R. constantinopolitanus (Arabic name: Hawd-
han fa'ri), commonly used in Eastern Mediterranean folk
medicine, using in-vitro models of inflammation. Previ-
ous work in our laboratory established an in-vitro model
of inflammation [26]. In this model, treatment of mouse
Exposure of SCp2 cells to Y2+3 at noncytotoxic concentrations reduces, in a concentration-dependent manner, ET-induced IL- 6 levels Figure 3
Exposure of SCp2 cells to Y2+3 at noncytotoxic concentrations reduces, in a concentration-dependent manner, 
ET-induced IL-6 levels. (A) SCp2 cells were treated on day 3 of culture with EtOH (Ctrl) or Y2+3 at different concentra-
tions in DM supplemented with 1% FBS. Forty-eight hr later, trypan blue assay was performed. SCp2 cells were treated (B) on 
day 3 of culture 30 min before ET (short-term exposure) or (C) for 3 days (long-term exposure), as of day 1 of culture, with 
EtOH (Ctrl) or Y2+3 at different concentrations. Cells were treated on day 3 with ET at 10 μg/ml in DM supplemented with 1% 
FBS and their media collected 9 hr post-ET. The values depicted are the means (± S.D.) of a triplicate treatment. Means with 
the same letter are not significantly different. Statistical significance of the difference from Ctrl+ET is with **P < 0.01 or ***P < 
0.001. (Ctrl, control; ET, endotoxin; IL-6, interleukin-6). -ET (white square); +ET (black square).
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Exposure of SCp2 cells to individual FA components of Y2+3 or a synthetic FA mix does not reduce ET-induced IL-6 levels Figure 4
Exposure of SCp2 cells to individual FA components of Y2+3 or a synthetic FA mix does not reduce ET-induced 
IL-6 levels. SCp2 cells were treated (A) on day 3 of culture 30 min before ET (short-term exposure) or (B) for 3 days (long-
term exposure), as of day 1 of culture, with EtOH (Ctrl), Y2+3
a, palmitate, linoleateb, oleate, stearate or a synthetic FA mix at 
different concentrations. Cells were treated on day 3 with ET at 10 μg/ml in DM supplemented with 1% FBS and their media 
collected 9 hr post-ET. The values depicted are the means (± S.D.) of a triplicate treatment. Statistical significance of the differ-
ence from Ctrl+ET is with ***P < 0.001. (Ctrl, control; -ET, untreated cells; IL-6, interleukin-6). aFor short-term exposure (A), 
cells were treated with Y2+3 at 10 μg/ml. bLong-term exposure (B) to linoleate at 5 μg/ml was cytotoxic to cells.
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mammary cells with ET at 10 μg/ml, a noncytotoxic con-
centration, enhanced nuclear factor (NF)-κB DNA-bind-
ing activity, suppressed β-casein expression and
upregulated pro-inflammatory mediators, including gela-
tinases (MMP-2 and MMP-9) and cytokines (IL-6 and
TNF-α). Consequently, SCp2 mouse mammary epithelial
cell strain was utilized to assess potential in-vitro  anti-
inflammatory activities in R. constantinopolitanus. In
reviewing the literature, we highlighted the role phenols,
flavonoids and terpenoids play in treating inflammation
[27]. Accordingly, I.2, the chloroform fraction derived
from the crude MeOH extract of the plant and presumably
rich in these compounds, was assessed for its anti-inflam-
matory effects in ET-treated SCp2 cells. Due to its impor-
tance in the transition from the acute to the chronic phase
of inflammation [28], IL-6 has been chosen as an inflam-
mation marker to be monitored in our study. I.2 signifi-
cantly reduced ET-induced IL-6 levels without altering cell
viability or morphology. From there, I.2 was further frac-
tionated and purified to yield a FA mix, Y2+3. Short- and
long-term exposure to Y2+3 generated an IL-6 inhibitory
profile similar to that of I.2 without causing cytotoxicity,
but at relatively lower concentrations, indicating that the
inhibitory effect noted in I.2 was possibly due to Y2+3.
Numerous reports have shown the occurrence of FAs in
members of the Ranunculaceae family [29-31]. Chemical
investigation demonstrated the presence of palmitic acid,
C18:2 and C18:1 isomers and stearic acid (1:5:8:1 ratio)
in Y2+3. In a similar study, these FAs, along with others,
were reported to exist in Ranunculus ternatus [30], a Chi-
nese medicinal plant used as an analgesic for headache
and toothache and for treating congestion, corneal ptery-
gium and malaria.
The comparison between the anti-inflammatory activity
of Y2+3 and other commonly known biologically active
FAs suggested that the higher potency of Y2+3 was not due
to its presumed FAs, i.e. palmitic and stearic acid and at
least not the two most common isomers of C18:2 and
Exposure of SCp2 cells to Y2+3 reduces ET-induced IL-6 levels more potently than fish oil and CLA Figure 5
Exposure of SCp2 cells to Y2+3 reduces ET-induced IL-6 levels more potently than fish oil and CLA. SCp2 cells 
were treated (A and C) on day 3 of culture 30 min before ET (short-term exposure) or (B and D) for 3 days (long-term 
exposure), as of day 1 of culture, with EtOH (Ctrl), Y2+3
a, fish oil (A and B) or CLAb (C and D) at different concentrations. 
Cells were treated on day 3 with ET at 10 μg/ml in DM supplemented with 1% FBS and their media collected 9 hr post-ET. The 
values depicted are the means (± S.D.) of a triplicate treatment. Statistical significance of the difference from Ctrl+ET is with 
**P < 0.01 or ***P < 0.001. (Ctrl, control; ET, endotoxin; IL-6, interleukin-6). aCells were treated with Y2+3 at 5 or 10 μg/ml for 
long- (B and D) and short-term (A and C) exposure, respectively. bShort- and long-term exposures to CLA at 5 and 3 μg/ml, respec-
tively, were cytotoxic to cells. -ET (white square); +ET (black square).
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C18:1: linoleic and oleic acid, respectively. Even when
tested at concentrations exceeding the ones normally
present in Y2+3 mix, none of the FAs reduced ET-induced
IL-6 levels. Furthermore, the synthetic FA mix, containing
these FAs in the same ratio as in Y2+3, did not reduce IL-6
levels in SCp2 cells. Y2+3 has demonstrated comparable
anti-inflammatory effects in IL-1-stimulated mouse intes-
tinal epithelial Mode-K cells. Y2+3 effectively downregu-
lated COX-2 expression in these cells, an activity not
noted in its synthetic FA mix. Nevertheless, the above
observations do not exclude potential combinatorial
effects for these FAs. This suggestion is supported by a
study that demonstrated antifertility activities in Aza-
dirachta indica seed extract and in one of its fractions (con-
taining palmitate, linoleate, oleate and stearate, in
addition to methyl palmitate and methyl oleate), which
were reduced upon further fractionation. In the same
study, regrouping the obtained subfractions to reconsti-
tute the original mixture in a similar proportion did not
regenerate the original biological activity [32]. This was
attributed to the synergism of the constituents of the mix-
ture as they existed in the seed. Although this could be the
Exposure of Mode-K cells to Y2+3, but not to a synthetic FA mix, reduces IL-1-induced COX-2 protein levels Figure 6
Exposure of Mode-K cells to Y2+3, but not to a synthetic FA mix, reduces IL-1-induced COX-2 protein levels. 
Mode-K cells were treated on day 2 of culture 8 or 12 hr before IL-1 (pretreatment) or on day 3 (cotreatment) with (A) Y2+3 
at 10 μg/ml or (B) a synthetic FA mix at different concentrations (Left: 10 μg/ml; Right: 60 μg/ml) in FBS-free medium. Cells 
were treated on day 3 with IL-1 at 10 ng/ml in the absence of FBS and their proteins extracted 6 or 8 hr post-IL-1 for western 
blot analysis. β-actin or GAPDH was used to demonstrate equal loading. (COX-2, cyclooxygenase-2; IL-1, interleukin-1).BMC Complementary and Alternative Medicine 2009, 9:44 http://www.biomedcentral.com/1472-6882/9/44
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case in our study, however, our results can be explained
also by possible occurrence of CLA and/or its precursor
vaccenic acid as the C18:2 and C18:1 isomers, respec-
tively. Knowing that the anti-inflammatory role of CLA,
unlike oleate, palmitate and stearate, was highlighted by
different studies [9,14], we opted to investigate the effect
of CLA on IL-6 production by SCp2 cells.
In addition, various reports demonstrated the efficacy of
CLA, EPA and DHA in reversing inflammation [2,33-36].
Our comparative studies denote similar or more potent
effects for Y2+3 in SCp2 cell culture model that could be
noticed within a shorter exposure time or with less cyto-
toxic effects. Compared to fish oil, Y2+3 was able to reduce
IL-6 levels within a shorter period of time; however, at
longer exposures, fish oil was more potent than Y2+3. Sim-
ilarly, CLA was less effective than Y2+3, even at the maxi-
mum noncytotoxic concentration for short durations, but
exhibited more potent effect after long-term exposure.
This suggests the presence of biologically active CLA iso-
mer(s) in Y2+3 that could be synergized by the other FA
constituents of Y2+3. Worth noting is the presence of a
marketable formula of CLA that contains, in addition, pal-
mitic, linoleic, oleic and stearic acid (Tonalin CLA,
WeightLossGuide, Sarasota, FL, USA).
Studies have confirmed that dietary PUFA supplementa-
tion is capable of ameliorating IBD [37,38]. For instance,
using a pig model of dextran sodium sulfate (DSS)-
induced colitis, both n-3 PUFA- and CLA-rich diets were
shown to exert anti-inflammatory effects [39]. In a related
preliminary study, Y2+3 synergized the anti-inflammatory
activities in salograviolide A (SA), a sesquiterpene lactone
purified from Centaurea ainetensis [24,40], whereby intra-
peritoneal (i.p.) administration of Y2+3:SA mix reduced
pro-inflammatory cytokine levels in colons of iodoaceta-
mide-induced ulcerative colitis (UC) rats (Data not
shown).
Conclusion
Y2+3, the naturally occurring FA combination derived from
R. constantinopolitanus, reduces ET-induced IL-6 levels and
IL-1-induced COX-2 expression in-vitro more efficiently
than the highly reputable CLA and fish oil and within a
shorter period of time. Our preliminary studies demon-
strate similar effects for Y2+3 in an in-vivo model of IBD,
making it a promising plant-derived anti-inflammatory
FA mix. The mechanism of action of this mixture and the
nature of its C18:1 and C18:2 isomers have not been fully
elucidated. Finally, a better understanding of the specific
cellular targets of Y2+3 could prove invaluable in determin-
ing the role played by FAs in inflammation prevention
and resolution.
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